<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00444626</url>
  </required_header>
  <id_info>
    <org_study_id>DGE00105</org_study_id>
    <nct_id>NCT00444626</nct_id>
  </id_info>
  <brief_title>A Study to Compare the Safety and Effectiveness of a Non-FDA Approved Device Dermal Gel Extra (DGE) and an FDA Approved Device for the Correction of Nasolabial Folds (NLFs)</brief_title>
  <official_title>A Subject- and Evaluator-Blinded, Randomized, Multi-Center Study to Evaluate the Safety and Effectiveness of Injection With DGE Injectable Gel as Compared to an FDA-Approved Dermal Filler in Subjects Undergoing Cutaneous Correction of Nasolabial Folds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mentor Worldwide, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to evaluate the safety and effectiveness of injection
      with DGE Injectable Gel (hyaluronic acid with lidocaine manufactured by Genzyme Biosurgery)
      as compared to injection with Restylane (a Food and Drug Administration (FDA) approved dermal
      filler) in patients undergoing cutaneous correction of the nasolabial folds (NLFs).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study included an Initial and a Repeat Treatment period.

      The Initial Treatment period was a subject and evaluator-blinded, randomized split face study
      in which subjects received DGE in one nasolabial fold and Restylane in the other nasolabial
      fold. Both safety and efficacy were evaluated.

      In the Repeat Treatment Period, participants received DGE in both NLFs. Safety was evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in the Blinded Evaluator's Assessment of Nasolabial Fold (NLF) Wrinkle Severity at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>This was a comparison of the mean change between Baseline and the Week 24 score (baseline minus week 24 scores) in the blinded evaluators' assessments of NLF wrinkle severity. A positive value for the mean change indicates an improvement.
Genzyme 6-Point Grading Scale (GGS) for NLF was used for the assessment. A GGS score of zero indicates no wrinkles and a score of 5 indicates very deep wrinkles with redundant folds.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participant's Pain Assessment During the Initial Treatment Measured on a Visual Analog Scale (VAS)</measure>
    <time_frame>Day 1</time_frame>
    <description>The pain experienced by each participant at the time of injection (time 0) and at 15 and 30 minutes after injection during the initial treatment visit was evaluated. Pain was measured using a VAS of 0 mm (no pain) to 100 mm (extreme pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Blinded Evaluator's Assessment of Nasolabial Folds (NLF) Wrinkle Severity at Week 36</measure>
    <time_frame>Week 36</time_frame>
    <description>Mean change between Baseline and the Week 36 score (Baseline minus week 36 scores) in the blinded evaluators' assessments of NLF wrinkle severity. A positive value for the mean change indicates an improvement.
Genzyme 6-Point Grading Scale (GGS) for NLF was used for the assessment. A GGS score of zero indicates no wrinkles and a score of 5 indicates very deep wrinkles with redundant folds.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With at Least a 1 Point Improvement From Baseline in the Blinded Evaluator's Assessment of Wrinkle Severity at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Count of participants with at least a 1-point improvement from Baseline in the Genzyme 6-Point Grading Scale (GGS) at Week 24. A GGS score of zero indicates no wrinkles and a score of 5 indicates very deep wrinkles with redundant folds.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Product Preference at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Participants indicated their product preference at Week 24 after Date of Optimal Correction (DOC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Product Preference at Week 36</measure>
    <time_frame>Week 36</time_frame>
    <description>Participants indicated their product preference at Week 36 after Date of Optimal Correction (DOC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events During the Initial Treatment Period</measure>
    <time_frame>Weeks 1-36</time_frame>
    <description>Counts of participants with treatment-emergent adverse events (AEs) from the time of injection up to Week 36. AEs are presented regardless of relationship to study device and/or procedure.
If a participant had more than one occurrence of the same AE, he/she was counted only once. The most severe occurrence of an AE, as well as the most extreme relationship of the AE to the device, was indicated in cases of multiple occurrences of the same AE. For AEs by relationship, procedure-related and device-related AEs are not mutually exclusive and therefore are not additive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events During the Repeat Treatment Period</measure>
    <time_frame>weeks 36 up to 47 weeks</time_frame>
    <description>Count of participants with treatment-emergent adverse events (AEs) from the time of injection for the repeat treatment period up to week 47. AEs are presented regardless of relationship to study device and/or procedure.
If a participant had more than one occurrence of the same AE, he/she was counted only once. The most severe occurrence of an AE, as well as most extreme relationship of the AE to the device, was indicated in cases of multiple occurrences of the same AE. For AEs by relationship, procedure-related and device-related AEs are not mutually exclusive and therefore are not additive.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Facial Wrinkles at the Nasolabial Folds</condition>
  <arm_group>
    <arm_group_label>DGE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received DGE in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period. Participants who continued into the Repeat Treatment period were treated with DGE as an open-label treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Restylane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received Restylane in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dermal Gel Extra (DGE)</intervention_name>
    <description>Dermal Gel Extra (DGE) Injectable Gel contains hyaluronic acid with lidocaine. DGE was administered to nasolabial folds via the intradermal route. The Principal Investigator was instructed to inject a sufficient amount of DGE to ensure full correction of the NLF wrinkles (i.e., to the optimal level of correction achievable). Up to 2 touch-up treatments were allowed in the Initial Treatment period.</description>
    <arm_group_label>DGE</arm_group_label>
    <other_name>PREVELLE Lift</other_name>
    <other_name>hyaluronic acid and lidocaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Restylane</intervention_name>
    <description>Restylane was administered to nasolabial folds via the intradermal route. The Principal Investigator was instructed to inject a sufficient amount of Restylane to ensure full correction of the NLF wrinkles (i.e., to the optimal level of correction achievable). Up to 2 touch-up treatments were allowed in the Initial Treatment period.</description>
    <arm_group_label>Restylane</arm_group_label>
    <other_name>dermal filler</other_name>
    <other_name>hyaluronic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EMLA Cream</intervention_name>
    <description>EMLA Cream (Eutectic Mixture of Local Anesthetics) is an FDA-approved topical anesthetic comprised of 2.5% each of lidocaine/prilocaine. EMLA Cream was applied in approximately equal amounts prior to all injections of DGE and Restylane.</description>
    <arm_group_label>DGE</arm_group_label>
    <arm_group_label>Restylane</arm_group_label>
    <other_name>lidocaine</other_name>
    <other_name>prilocaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (abbreviated list):

          -  Bilateral nasolabial folds (NLF) with severity score of 3 or 4 on the 6 point scale.

        Exclusion Criteria (abbreviated list):

          -  Pregnant/lactating women.

          -  Subjects who have an allergy to lidocaine, prilocaine or other amide-type anesthetic.

          -  Had a chemical peel at the NLF area within 4 weeks prior to study entry. In addition,
             subjects were restricted from undergoing chemical peels at the NLF area for the
             duration of the study.

          -  Had any treatment with Botox® injections in the upper 1/3 of the face within 2 weeks
             prior to entry into the study, or in the lower 2/3 of the face within 24 weeks prior
             to entry. In addition, subjects were restricted from receiving Botox injections in the
             face for the duration of the study.

          -  Received prior therapy to the face and/or neck (e.g., dermabrasion, face-lift,
             Thermage®,laser resurfacing, contour threads, non-ablative laser treatments) within 24
             weeks prior to study entry. In addition, subjects were restricted from undergoing such
             therapy for the duration of the study.

          -  Had previous tissue augmentation at the NLF area within 24 weeks prior to study entry.
             In addition, subjects were restricted from undergoing tissue augmentation at the NLF
             area for the duration of the study.

          -  Had previous treatment at the NLF area with permanent implants (e.g.,
             silicone,Softform®) or long-lasting fillers (e.g., RadiesseTM, Sculptra®, ArteFill®
             [Artecoll], or Bio-AlcamidTM). In addition, subjects were restricted from undergoing
             treatment with permanent implants or long-lasting fillers at the NLF area for the
             duration of the study.

          -  Had evidence of scar-related disease or delayed healing activity within one year prior
             to study enrollment. (Note: subjects with scars were eligible for study enrollment,
             although scars at the intended treatment sites were not treated.)

          -  Had a history of keloid formation.

          -  Had a history of hypo- or hyperpigmentation of the skin.

          -  Had any infection, unhealed wound, or active inflammatory process (e.g., skin
             eruptions such as cysts, pimples, rashes, or hives) at the injection site(s).

          -  Immunocompromised/immunosuppressed (e.g., HIV-positive, transplant recipient, or
             presently receiving chemotherapy).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Genzyme, a Sanofi Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Westwood</city>
        <state>New Jersey</state>
        <zip>07675</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>White Plains</city>
        <state>New York</state>
        <zip>10640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2007</study_first_submitted>
  <study_first_submitted_qc>March 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2007</study_first_posted>
  <results_first_submitted>April 7, 2015</results_first_submitted>
  <results_first_submitted_qc>April 7, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 22, 2015</results_first_posted>
  <disposition_first_submitted>December 10, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>December 10, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 14, 2009</disposition_first_posted>
  <last_update_submitted>April 7, 2015</last_update_submitted>
  <last_update_submitted_qc>April 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nasolabial folds</keyword>
  <keyword>facial wrinkles</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Prilocaine</mesh_term>
    <mesh_term>EMLA</mesh_term>
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>166 subjects screened, 26 subjects were never randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Combined Arm</title>
          <description>Participants received DGE in one nasolabial fold (NLF) on one side of their face and Restylane in one NLF on the other side of their face (blinded, split-face study design) in the Initial Treatment. For participants who continued into the Repeat Treatment Period, they received DGE in both NLFs as an open-label treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Initial Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="140"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="128"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Repeat Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="105">23 subjects withdrew after completing the Initial Treatment and did not enter the Repeat Treatment</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Combined Arms</title>
          <description>Participants received DGE in one nasolabial fold (NLF) on one side of their face and Restylane in one NLF on the other side of their face (blinded, split-face study design) in the Initial Treatment. For participants who continued into the Repeat Treatment Period, they received DGE in both NLFs as an open-label treatment.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="140"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.7" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Multiple responses were possible for race as the screening visit CRF stated “check all that apply”.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaskan Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Available</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in the Blinded Evaluator’s Assessment of Nasolabial Fold (NLF) Wrinkle Severity at Week 24</title>
        <description>This was a comparison of the mean change between Baseline and the Week 24 score (baseline minus week 24 scores) in the blinded evaluators' assessments of NLF wrinkle severity. A positive value for the mean change indicates an improvement.
Genzyme 6-Point Grading Scale (GGS) for NLF was used for the assessment. A GGS score of zero indicates no wrinkles and a score of 5 indicates very deep wrinkles with redundant folds.</description>
        <time_frame>Week 24</time_frame>
        <population>The Full Analysis Set (FAS) population includes all randomized participants who received both study treatments and had some post-treatment effectiveness data. For the effectiveness analyses based on the FAS population, participants were analyzed as randomized. The FAS population was identical to an intent-to-treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>Dermal Gel Extra (DGE)</title>
            <description>Participants received DGE in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period. Participants who continued into the Repeat Treatment Period received DGE in all NLFs as an open-label treatment.</description>
          </group>
          <group group_id="O2">
            <title>Restylane</title>
            <description>Participants received Restylane in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Blinded Evaluator’s Assessment of Nasolabial Fold (NLF) Wrinkle Severity at Week 24</title>
          <description>This was a comparison of the mean change between Baseline and the Week 24 score (baseline minus week 24 scores) in the blinded evaluators' assessments of NLF wrinkle severity. A positive value for the mean change indicates an improvement.
Genzyme 6-Point Grading Scale (GGS) for NLF was used for the assessment. A GGS score of zero indicates no wrinkles and a score of 5 indicates very deep wrinkles with redundant folds.</description>
          <population>The Full Analysis Set (FAS) population includes all randomized participants who received both study treatments and had some post-treatment effectiveness data. For the effectiveness analyses based on the FAS population, participants were analyzed as randomized. The FAS population was identical to an intent-to-treat population.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>nasolabial folds</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="1.0"/>
                    <measurement group_id="O2" value="1.8" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant’s Pain Assessment During the Initial Treatment Measured on a Visual Analog Scale (VAS)</title>
        <description>The pain experienced by each participant at the time of injection (time 0) and at 15 and 30 minutes after injection during the initial treatment visit was evaluated. Pain was measured using a VAS of 0 mm (no pain) to 100 mm (extreme pain).</description>
        <time_frame>Day 1</time_frame>
        <population>The Full Analysis Set (FAS) population includes all randomized participants who received both study treatments and had some post-treatment effectiveness data. For the effectiveness analyses based on the FAS population, participants were analyzed as randomized. The FAS population was identical to an intent-to-treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>Dermal Gel Extra (DGE)</title>
            <description>Participants received DGE in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period. Participants who continued into the Repeat Treatment Period received DGE in all NLFs as an open-label treatment.</description>
          </group>
          <group group_id="O2">
            <title>Restylane</title>
            <description>Participants received Restylane in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Participant’s Pain Assessment During the Initial Treatment Measured on a Visual Analog Scale (VAS)</title>
          <description>The pain experienced by each participant at the time of injection (time 0) and at 15 and 30 minutes after injection during the initial treatment visit was evaluated. Pain was measured using a VAS of 0 mm (no pain) to 100 mm (extreme pain).</description>
          <population>The Full Analysis Set (FAS) population includes all randomized participants who received both study treatments and had some post-treatment effectiveness data. For the effectiveness analyses based on the FAS population, participants were analyzed as randomized. The FAS population was identical to an intent-to-treat population.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 time after injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.2" spread="20.3"/>
                    <measurement group_id="O2" value="48.9" spread="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes after injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="10.1"/>
                    <measurement group_id="O2" value="16.3" spread="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes after injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="7.0"/>
                    <measurement group_id="O2" value="7.9" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Blinded Evaluator’s Assessment of Nasolabial Folds (NLF) Wrinkle Severity at Week 36</title>
        <description>Mean change between Baseline and the Week 36 score (Baseline minus week 36 scores) in the blinded evaluators' assessments of NLF wrinkle severity. A positive value for the mean change indicates an improvement.
Genzyme 6-Point Grading Scale (GGS) for NLF was used for the assessment. A GGS score of zero indicates no wrinkles and a score of 5 indicates very deep wrinkles with redundant folds.</description>
        <time_frame>Week 36</time_frame>
        <population>The Full Analysis Set (FAS) population includes all randomized participants who received both study treatments and had some post-treatment effectiveness data. For the effectiveness analyses based on the FAS population, participants were analyzed as randomized. The FAS population was identical to an intent-to-treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>Dermal Gel Extra (DGE)</title>
            <description>Participants received DGE in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period. Participants who continued into the Repeat Treatment Period received DGE in all NLFs as an open-label treatment.</description>
          </group>
          <group group_id="O2">
            <title>Restylane</title>
            <description>Participants received Restylane in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Blinded Evaluator’s Assessment of Nasolabial Folds (NLF) Wrinkle Severity at Week 36</title>
          <description>Mean change between Baseline and the Week 36 score (Baseline minus week 36 scores) in the blinded evaluators' assessments of NLF wrinkle severity. A positive value for the mean change indicates an improvement.
Genzyme 6-Point Grading Scale (GGS) for NLF was used for the assessment. A GGS score of zero indicates no wrinkles and a score of 5 indicates very deep wrinkles with redundant folds.</description>
          <population>The Full Analysis Set (FAS) population includes all randomized participants who received both study treatments and had some post-treatment effectiveness data. For the effectiveness analyses based on the FAS population, participants were analyzed as randomized. The FAS population was identical to an intent-to-treat population.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>nasolabial folds</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="1.2"/>
                    <measurement group_id="O2" value="1.3" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With at Least a 1 Point Improvement From Baseline in the Blinded Evaluator’s Assessment of Wrinkle Severity at Week 24</title>
        <description>Count of participants with at least a 1-point improvement from Baseline in the Genzyme 6-Point Grading Scale (GGS) at Week 24. A GGS score of zero indicates no wrinkles and a score of 5 indicates very deep wrinkles with redundant folds.</description>
        <time_frame>Week 24</time_frame>
        <population>The Full Analysis Set (FAS) population includes all randomized participants who received both study treatments and had some post-treatment effectiveness data. For the effectiveness analyses based on the FAS population, participants were analyzed as randomized. The FAS population was identical to an intent-to-treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>Dermal Gel Extra (DGE)</title>
            <description>Participants received DGE in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period. Participants who continued into the Repeat Treatment Period received DGE in all NLFs as an open-label treatment.</description>
          </group>
          <group group_id="O2">
            <title>Restylane</title>
            <description>Participants received Restylane in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With at Least a 1 Point Improvement From Baseline in the Blinded Evaluator’s Assessment of Wrinkle Severity at Week 24</title>
          <description>Count of participants with at least a 1-point improvement from Baseline in the Genzyme 6-Point Grading Scale (GGS) at Week 24. A GGS score of zero indicates no wrinkles and a score of 5 indicates very deep wrinkles with redundant folds.</description>
          <population>The Full Analysis Set (FAS) population includes all randomized participants who received both study treatments and had some post-treatment effectiveness data. For the effectiveness analyses based on the FAS population, participants were analyzed as randomized. The FAS population was identical to an intent-to-treat population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Product Preference at Week 24</title>
        <description>Participants indicated their product preference at Week 24 after Date of Optimal Correction (DOC).</description>
        <time_frame>Week 24</time_frame>
        <population>The Full Analysis Set (FAS) population includes all randomized participants who received both study treatments and had some post-treatment effectiveness data. For the effectiveness analyses based on the FAS population, participants were analyzed as randomized. The FAS population was identical to an intent-to-treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>Dermal Gel Extra (DGE)</title>
            <description>Participants received DGE in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period. Participants who continued into the Repeat Treatment Period received DGE in all NLFs as an open-label treatment.</description>
          </group>
          <group group_id="O2">
            <title>Restylane</title>
            <description>Participants received Restylane in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Product Preference at Week 24</title>
          <description>Participants indicated their product preference at Week 24 after Date of Optimal Correction (DOC).</description>
          <population>The Full Analysis Set (FAS) population includes all randomized participants who received both study treatments and had some post-treatment effectiveness data. For the effectiveness analyses based on the FAS population, participants were analyzed as randomized. The FAS population was identical to an intent-to-treat population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Product Preference at Week 36</title>
        <description>Participants indicated their product preference at Week 36 after Date of Optimal Correction (DOC).</description>
        <time_frame>Week 36</time_frame>
        <population>The Full Analysis Set (FAS) population includes all randomized participants who received both study treatments and had some post-treatment effectiveness data. For the effectiveness analyses based on the FAS population, participants were analyzed as randomized. The FAS population was identical to an intent-to-treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>Dermal Gel Extra (DGE)</title>
            <description>Participants received DGE in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period. Participants who continued into the Repeat Treatment Period received DGE in all NLFs as an open-label treatment.</description>
          </group>
          <group group_id="O2">
            <title>Restylane</title>
            <description>Participants received Restylane in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Product Preference at Week 36</title>
          <description>Participants indicated their product preference at Week 36 after Date of Optimal Correction (DOC).</description>
          <population>The Full Analysis Set (FAS) population includes all randomized participants who received both study treatments and had some post-treatment effectiveness data. For the effectiveness analyses based on the FAS population, participants were analyzed as randomized. The FAS population was identical to an intent-to-treat population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events During the Initial Treatment Period</title>
        <description>Counts of participants with treatment-emergent adverse events (AEs) from the time of injection up to Week 36. AEs are presented regardless of relationship to study device and/or procedure.
If a participant had more than one occurrence of the same AE, he/she was counted only once. The most severe occurrence of an AE, as well as the most extreme relationship of the AE to the device, was indicated in cases of multiple occurrences of the same AE. For AEs by relationship, procedure-related and device-related AEs are not mutually exclusive and therefore are not additive.</description>
        <time_frame>Weeks 1-36</time_frame>
        <population>Number of patients randomized to initial treatment phase. Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Dermal Gel Extra (DGE)</title>
            <description>Participants received DGE in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period. Participants who continued into the Repeat Treatment Period, they received DGE in all NLFs as an open-label treatment.</description>
          </group>
          <group group_id="O2">
            <title>Restylane</title>
            <description>Participants received Restylane in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Non-NLF</title>
            <description>Adverse events that did not occur at the nasolabial folds</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events During the Initial Treatment Period</title>
          <description>Counts of participants with treatment-emergent adverse events (AEs) from the time of injection up to Week 36. AEs are presented regardless of relationship to study device and/or procedure.
If a participant had more than one occurrence of the same AE, he/she was counted only once. The most severe occurrence of an AE, as well as the most extreme relationship of the AE to the device, was indicated in cases of multiple occurrences of the same AE. For AEs by relationship, procedure-related and device-related AEs are not mutually exclusive and therefore are not additive.</description>
          <population>Number of patients randomized to initial treatment phase. Safety Population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with at least one Adverse Event (AE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="89"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs by Severity - Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs by Severity - Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs by Severity - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs by Relationship - Procedure or Device</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="87"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs by Relationship - Procedure Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs by Relationship - Device Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="78"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs by Duration - less than or equal to 7 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs by Duration - more than 7 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs by Treatment - No Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs by Treatment - Medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs by Treatment - Non-drug Therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs by Treatment - Hospitalization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with Baseline AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with Serious AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with Study Discontinuation due to AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events During the Repeat Treatment Period</title>
        <description>Count of participants with treatment-emergent adverse events (AEs) from the time of injection for the repeat treatment period up to week 47. AEs are presented regardless of relationship to study device and/or procedure.
If a participant had more than one occurrence of the same AE, he/she was counted only once. The most severe occurrence of an AE, as well as most extreme relationship of the AE to the device, was indicated in cases of multiple occurrences of the same AE. For AEs by relationship, procedure-related and device-related AEs are not mutually exclusive and therefore are not additive.</description>
        <time_frame>weeks 36 up to 47 weeks</time_frame>
        <population>Safety Population for repeat treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Dermal Gel Extra (DGE)</title>
            <description>Participants received DGE in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period. Participants who continued into the Repeat Treatment Period, they received DGE in all NLFs as an open-label treatment.</description>
          </group>
          <group group_id="O2">
            <title>Restylane - Dermal Gel Extra (DGE)</title>
            <description>Participants received Restylane in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period. In the Repeat Treatment Period, participants received DGE on both sides of their face. This represents the experience with DGE for the side of the face that was originally treated with Restylane.</description>
          </group>
          <group group_id="O3">
            <title>Non-NLF</title>
            <description>Adverse events that did not occur at the nasolabial folds</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events During the Repeat Treatment Period</title>
          <description>Count of participants with treatment-emergent adverse events (AEs) from the time of injection for the repeat treatment period up to week 47. AEs are presented regardless of relationship to study device and/or procedure.
If a participant had more than one occurrence of the same AE, he/she was counted only once. The most severe occurrence of an AE, as well as most extreme relationship of the AE to the device, was indicated in cases of multiple occurrences of the same AE. For AEs by relationship, procedure-related and device-related AEs are not mutually exclusive and therefore are not additive.</description>
          <population>Safety Population for repeat treatment.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with at least one Adverse Event (AE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs by Severity - Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs by Severity - Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs by Severity - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs by Relationship - Procedure or Device (DGE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs by Relationship - Procedure Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs by Relationship - Device (DGE) Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs by Duration - less than or equal to 7 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs by Duration - more than 7 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs by Treatment - No Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs by Treatment - Medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs by Treatment - Non-drug Therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs by Treatment - Hospitalization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with a Serious AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with Study Discontinuation due to AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Initial Treatment Period (week 1 to week 36) and Repeat Treatment Period (week 36 up to week 47)</time_frame>
      <desc>Participant counts of AEs are broken out by Initial Treatment Period and Repeat Treatment Period. Then further summarized as AEs occurring at the nasolabial fold initially treated with DGE, the nasolabial fold initially treated with Restylane, and AEs that did not occur at the nasolabial folds.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dermal Gel Extra (DGE): Initial Treatment Period</title>
          <description>Adverse events that occurred at the nasolabial fold treated with DGE, and occurred during the Initial Treatment Period regardless of relationship to DGE treatment.</description>
        </group>
        <group group_id="E2">
          <title>Restylane: Initial Treatment Period</title>
          <description>Adverse events that occurred at the nasolabial fold treated with Restylane, and occurred during the Initial Treatment Period regardless of relationship to Restylane treatment.</description>
        </group>
        <group group_id="E3">
          <title>Non-NLF: Initial Treatment Period</title>
          <description>Adverse events that did not occur at the nasolabial folds, and occurred during the Initial Treatment Period regardless to relationship to either DGE or Restylane treatment.</description>
        </group>
        <group group_id="E4">
          <title>Dermal Gel Extra (DGE) - Repeat Treatment Period</title>
          <description>Adverse events that occurred at the nasolabial fold that was treated with DGE in the Initial Treatment Period, and occurred during the Repeat Treatment Period regardless of relationship to DGE treatment.</description>
        </group>
        <group group_id="E5">
          <title>Restylane - Dermal Gel Extra (DGE) - Repeat Treatment Period</title>
          <description>Adverse events that occurred at the nasolabial fold that was treated with Restylane in the Initial Treatment Period, and occurred during the Repeat Treatment Period regardless of relationship to DGE treatment.</description>
        </group>
        <group group_id="E6">
          <title>Non-NLF: Repeat Treatment Period</title>
          <description>Adverse events that did not occur at the nasolabial folds, and occurred during the Repeat Treatment Period regardless to relationship to DGE treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <description>Reported by investigator as unrelated to study device.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <description>Reported by investigator as unrelated to study device.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="55" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="52" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Localised intraabdominal fluid collection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Oral disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Lip swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="47" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="47" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="32" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="33" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Injection site nodule</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Injection site anaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Injection site paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Injection site discolouration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Injection site discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Injection site dryness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Injection site inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Injection site papule</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Injection site pustule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Open wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Post procedural diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Post procedural swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Postoperative constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Procedural nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Bone density decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Intraocular pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Osteopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Resorption bone increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Postnasal drip</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Principal investigators (PI) will give Genzyme a draft manuscript or draft publication 60 days before publication. Genzyme will make every reasonable attempt to review publication or manuscript and give feedback in such 60 day period. PI will not use Genzyme confidential information without prior written consent.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Genzyme Medical Information (MedInfo)</name_or_title>
      <organization>Genzyme</organization>
      <email>medinfo@genzyme.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

